NVSEF Financials 07/16/2014 01:38:53 Novartis AG

NVSEF Financials 07/16/2014 01:38:53
Novartis AG
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 58,831,000 57,561,000 59,375,000 51,561,000
Cost of Revenue 19,608,000 18,756,000 18,983,000 14,488,000
Gross Profit 39,223,000 38,805,000 40,392,000 37,073,000
Operating Expenses
Research and Development 9,852,000 9,332,000 9,583,000 9,070,000
Sales, General and Admin. 18,461,000 18,280,000 20,029,000 16,477,000
Non-Recurring Items - - - -
Other - - - -
Operating Income 10,910,000 11,193,000 10,780,000 11,526,000
Income From Continuing Operations
Add'l Income/Expense Items (92,000) (96,000) (2,000) 64,000
Earnings Before Interest and Tax 11,418,000 11,649,000 11,306,000 12,394,000
Interest Expense 683,000 724,000 751,000 692,000
Earnings Before Tax 10,735,000 10,925,000 10,555,000 11,702,000
Income Tax 1,443,000 1,542,000 1,483,000 1,733,000
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary 600,000 552,000 528,000 804,000
Net Income Cont. Operations 9,892,000 9,935,000 9,600,000 10,773,000
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 9,292,000 9,383,000 9,072,000 9,969,000
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 9,292,000 9,383,000 9,072,000 9,969,000